NCT05676489 is a EARLY_PHASE1 clinical trial of [F-18]MeFAMP PET in Healthy Volunteers, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT05676489?

NCT05676489 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT05676489?

Interventions in NCT05676489: [F-18]MeFAMP PET.

What condition does NCT05676489 study?

NCT05676489 studies Healthy Volunteers, Recurrent Glioma, Brain Metastases From Extra-cranial Solid Tumors.

Is NCT05676489 still recruiting?

NCT05676489 is currently not yet recruiting. Last updated 20 February 2026.

Last reviewed 2026-02-20 · How we verify

NCT05676489

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors

Not yet recruiting EARLY_PHASE1 Last updated 20 February 2026

What this trial tests

EARLY_PHASE1 trial testing [F-18]MeFAMP PET in Healthy Volunteers in 28 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
30 August 2027

30 August 2027

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	28
Start date	1 April 2026
Primary completion	30 August 2027
Estimated completion	30 August 2027
Sites	1 location across United States

Drugs / interventions tested

[F-18]MeFAMP PET — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →
Recurrent Glioma — all drugs for Recurrent Glioma →
Brain Metastases From Extra-cranial Solid Tumors — all drugs for Brain Metastases From Extra-cranial Solid Tumors →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 Months to 89, any sex, with Healthy Volunteers or Recurrent Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This first-in-human study will establish the human safety and radiation dosimetry of the system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET) imaging of primary and metastatic brain tumors. This study will include 3 cohorts: healthy volunteers for whole body dosimetry estimates (n=6-8, Dosimetry Cohort), patients undergoing evaluation for recurrent high grade glioma after radiation therapy (n=10, high grade glioma (HGG) Cohort), and patients with brain metastases from extra-cranial solid tumors before and after radiation therapy (n=10, Metastasis Cohort). Exploratory assessment of the diagnostic accuracy of MeFAMP for distinguishing recurrent/progressive brain tumors from radiation-related treatment effects will also be performed for subsequent trial design. The study will complete accrual and safety assessment in the Dosimetry Cohort before recruiting for the HGG and Metastasis Cohorts.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model
Akca U, Zhang Y, Yasui N, Hensley C, et al · · 2025
Preclinical Comparison of <sup>18</sup>F-Labeled Amino Acids Targeting Different Transporter Systems for PET Imaging of Triple-Negative Breast Cancer.
Akca U, Song PN, Devalankar D, Yasui N, et al · · 2026 · PMID 41506804 · DOI 10.2967/jnumed.125.270225

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05676489 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 20 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05676489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing